Pay in 4 interest-free payments of $7.40 Learn more
Ships within 48 hours · Estimated delivery Aug 3 - Aug 8
San Francisco-based biotech Structure Therapeutics (NASDAQ:GPCR) has reported Phase 2 topline results for its oral GLP-1 candidate aleniglipron, posting weight-loss outcomes the company says stack up favourably against leading next-generation drugs including Eli Lilly and Co (NYSE:LLY)s oral candidate orforglipron, which is widely expected to reach the market in the near term
A critical step in the production of peptide therapeutics is downstream purification, where technologies such as reversed-phase (RP) and ion exchange (IEX) chromatography are employed to remove impurities, truncated sequences, and byproducts
Disclosure: The STOP Obesity Alliance and the Obesity Action Coalition receive financial support from companies that produce GLP-1 medications
Interest in radiation wounds, hypertrophic scars
US$ 20.49
US$ 29.62
US$ 27.80
US$ 21.46
US$ 21.93
